These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8222499)

  • 1. Efficacy and tolerability of the renin inhibitor Ro 42-5892 in patients with hypertension.
    Rongen GA; Lenders JW; Kleinbloesem CH; Weber C; Welker H; Fahrner E; Pozenel H; Woittiez AJ; Haug G; Buchmann MS
    Clin Pharmacol Ther; 1993 Nov; 54(5):567-77. PubMed ID: 8222499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.
    van den Meiracker AH; Admiraal PJ; Man in 't Veld AJ; Derkx FH; Ritsema van Eck HJ; Mulder P; van Brummelen P; Schalekamp MA
    BMJ; 1990 Jul; 301(6745):205-10. PubMed ID: 2203486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension.
    Kobrin I; Viskoper RJ; Laszt A; Bock J; Weber C; Charlon V
    Am J Hypertens; 1993 May; 6(5 Pt 1):349-56. PubMed ID: 8512659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time dependency of the antihypertensive efficacy of the new renin inhibitor Ro 42-5892.
    Viskoper RJ; Charlon V; Laszt A; Yosefy C; Bock J; Landau M; Kobrin I
    J Hum Hypertens; 1994 Feb; 8(2):133-6. PubMed ID: 8207739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
    Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system.
    Himmelmann A; Bergbrant A; Svensson A; Hansson L; Aurell M
    Am J Hypertens; 1996 Jun; 9(6):517-22. PubMed ID: 8783774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
    Oparil S; Yarows SA; Patel S; Fang H; Zhang J; Satlin A
    Lancet; 2007 Jul; 370(9583):221-229. PubMed ID: 17658393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
    Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
    Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
    Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
    Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority trial.
    Hong SJ; Ahn TH; Baek SH; Cho WH; Jeon HK; Kwan J; Yoon MH; Lee KJ; Lim DS
    Clin Ther; 2006 Apr; 28(4):537-51. PubMed ID: 16750465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
    Stanton A; Jensen C; Nussberger J; O'Brien E
    Hypertension; 2003 Dec; 42(6):1137-43. PubMed ID: 14597641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension.
    Jones-Burton C; Rubino J; Roy S; Mai Y; Meehan A; Bellet M; Feig P
    J Am Soc Hypertens; 2010; 4(5):219-26. PubMed ID: 20705534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
    Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Smith B; Weissbach N; Maboudian M; Botha J; van Ingen H
    Circulation; 2009 Jan; 119(3):417-25. PubMed ID: 19139391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.
    Oh BH; Mitchell J; Herron JR; Chung J; Khan M; Keefe DL
    J Am Coll Cardiol; 2007 Mar; 49(11):1157-63. PubMed ID: 17367658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.